Form 8-K - Current report:
SEC Accession No. 0001140361-25-001687
Filing Date
2025-01-23
Accepted
2025-01-23 11:15:17
Documents
14
Period of Report
2025-01-23
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20042040_8k.htm   iXBRL 8-K 28674
2 EXHIBIT 99.1 ef20042040_ex99-1.htm EX-99.1 22133
  Complete submission text file 0001140361-25-001687.txt   195097

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA galt-20250123.xsd EX-101.SCH 4018
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE galt-20250123_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE galt-20250123_pre.xml EX-101.PRE 16068
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20042040_8k_htm.xml XML 4245
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

EIN.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31791 | Film No.: 25548586
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)